Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.39 |
| ▸ | WNT1 | P04628 | 10/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699090 | 0.91 | DYRK1A (0.42) | GSK3BDYRK1AWNT1KARS1BRAF | |
| SCHEMBL16776300 | 0.89 | KARS1 (0.34) | GSK3BDYRK1AWNT1KARS1BRAF | |
| SCHEMBL20631481 | 0.86 | GAA (0.38) | DYRK1AKARS1 | |
| SCHEMBL20632784 | 0.84 | KARS1 (0.38) | GSK3BDYRK1AKARS1 | |
| SCHEMBL20631665 | 0.82 | SLC9A1 (0.35) | KARS1 | |
| SCHEMBL17618330 | 0.82 | IMPDH2 (0.45) | BRAFIMPDH2BRD4CREBBP | |
| SCHEMBL19706100 | 0.80 | DYRK1A (0.39) | GSK3BDYRK1AWNT1BRAFBRD4 | |
| SCHEMBL17624498 | 0.80 | RHOA (0.40) | GSK3BDYRK1AWNT1KARS1BRAF | |
| SCHEMBL16775780 | 0.80 | IMPDH2 (0.37) | GSK3BDYRK1AWNT1KARS1BRAF | |
| SCHEMBL20632380 | 0.79 | USP2 (0.36) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 1728/4885DYRK1A 2623/4885WNT1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.